CA2147606A1 - Stable Extended Release Oral Dosage Composition - Google Patents

Stable Extended Release Oral Dosage Composition

Info

Publication number
CA2147606A1
CA2147606A1 CA2147606A CA2147606A CA2147606A1 CA 2147606 A1 CA2147606 A1 CA 2147606A1 CA 2147606 A CA2147606 A CA 2147606A CA 2147606 A CA2147606 A CA 2147606A CA 2147606 A1 CA2147606 A1 CA 2147606A1
Authority
CA
Canada
Prior art keywords
oral dosage
extended release
release oral
dosage composition
stable extended
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2147606A
Other languages
French (fr)
Other versions
CA2147606C (en
Inventor
Henry K. Kwan
Stephen M. Liebowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2147606A1 publication Critical patent/CA2147606A1/en
Application granted granted Critical
Publication of CA2147606C publication Critical patent/CA2147606C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Abstract

A film-coated extended release oral dosage composition containing the nasal decongestant pseudoephedrine or salt there-of, e.g., pseudoephedrine sulfate in a unique polymer matrix core and a film-coating on such core containing the non-sedating antihistamine, loratadine, and use of the said composition for treating patients showing the signs and symptoms associated with upper respiratory diseases and nasal congestion are disclosed.
CA002147606A 1992-10-23 1993-10-21 Stable extended release oral dosage composition Expired - Lifetime CA2147606C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/965,470 1992-10-23
US07/965,470 US5314697A (en) 1992-10-23 1992-10-23 Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
PCT/US1993/009873 WO1994009761A1 (en) 1992-10-23 1993-10-21 Stable extended release oral dosage composition

Publications (2)

Publication Number Publication Date
CA2147606A1 true CA2147606A1 (en) 1994-05-11
CA2147606C CA2147606C (en) 2000-10-10

Family

ID=25510010

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002147606A Expired - Lifetime CA2147606C (en) 1992-10-23 1993-10-21 Stable extended release oral dosage composition

Country Status (28)

Country Link
US (1) US5314697A (en)
EP (1) EP0665744B1 (en)
JP (1) JP3580815B2 (en)
KR (1) KR100283709B1 (en)
CN (1) CN1038474C (en)
AT (1) ATE161420T1 (en)
AU (1) AU676229B2 (en)
CA (1) CA2147606C (en)
CZ (1) CZ287687B6 (en)
DE (1) DE69316023T2 (en)
DK (1) DK0665744T3 (en)
EE (1) EE03106B1 (en)
ES (1) ES2110633T3 (en)
FI (1) FI112916B (en)
GR (1) GR3026198T3 (en)
HK (1) HK1004327A1 (en)
HU (1) HU220629B1 (en)
IL (1) IL107354A (en)
MY (1) MY109090A (en)
NO (1) NO308771B1 (en)
NZ (1) NZ257447A (en)
PH (1) PH29940A (en)
PL (1) PL172862B1 (en)
SG (1) SG42947A1 (en)
SK (1) SK281090B6 (en)
TW (1) TW251239B (en)
WO (1) WO1994009761A1 (en)
ZA (1) ZA937830B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171618B1 (en) 1996-05-29 2001-01-09 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010996A1 (en) * 1993-07-21 1996-04-18 The University Of Kentucky Research Foundation A multicompartment hard capsule with control release properties
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
PT812195E (en) * 1995-02-28 2003-03-31 Aventis Pharma Inc PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALCANOL COMPOUNDS
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
JP2000505104A (en) * 1996-10-31 2000-04-25 シェーリング コーポレイション Composition comprising loratadine and a decongestant for the treatment of asthma
PE71699A1 (en) * 1997-02-07 1999-08-03 Sepracor Inc PHARMACEUTICAL COMPOSITION OF DECARBOETOXYLORATADINE WITHOUT LACTOSE, NON-HYGROSCOPIC AND ANHYDRA
BE1011045A3 (en) 1997-03-14 1999-04-06 Ucb Sa Pharmaceutical composition for controlled release of active substances.
IL133420A (en) * 1997-08-26 2004-07-25 Aventis Pharma Inc Pharmaceutical composition in form of tablet comprising combination of antihistaminic piperidinoalkanol with decongestant sympathomimetic drug
PA8481801A1 (en) * 1998-09-10 2000-09-29 Schering Corp METHODS AND COMPOSITIONS FOR TREATING SINUSITIS, OTITIS MEDIA AND OTHER RELATED DISORDERS USING ANTIHISTAMINES
US6051585A (en) * 1998-12-07 2000-04-18 Weinstein; Robert E. Single-dose antihistamine/decongestant formulations for treating rhinitis
US6521254B2 (en) 1998-12-07 2003-02-18 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
KR100505899B1 (en) * 1999-02-23 2005-08-01 주식회사유한양행 Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
AU2697100A (en) * 1999-02-23 2000-09-14 Yuhan Corporation Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6267986B1 (en) 1999-09-24 2001-07-31 Ranbaxy Laboratories Limited Process for the preparation of a controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
AU2276801A (en) * 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
SK287684B6 (en) * 1999-12-20 2011-06-06 Schering Corporation Sustained release solid oral pharmaceutical dosage composition
US6613357B2 (en) * 2000-01-13 2003-09-02 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
US7147870B2 (en) * 2000-01-13 2006-12-12 Osmotica Corp. Osmotic device containing pseudoephedrine and an H1 antagonist
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
EP1276502A1 (en) * 2000-04-14 2003-01-22 J-Med Pharmaceuticals, Inc. Single-dose antihistamine/decongestant formulations for treating rhinitis
US20020094345A1 (en) * 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
JP2004534820A (en) * 2001-06-20 2004-11-18 シェーリング　コーポレイション Antihistamines for the treatment of nasal congestion and nasal obstruction
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
AU2002351655A1 (en) * 2002-08-29 2004-03-19 Osmotica Corp. Device for release of a drug containing oseltamivir and a h1 antagonist
US20040051686A1 (en) * 2002-09-17 2004-03-18 Yuan-Sung Weng Carry-on device having functions of both digital photographing and timing
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
MXPA06003450A (en) * 2003-09-26 2006-08-31 Johnson & Johnson Drug coating providing high drug loading and methods for providing the same.
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20070116764A1 (en) * 2003-12-01 2007-05-24 Shigeyuki Marunaka Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing
US20050266032A1 (en) * 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
SE0401031D0 (en) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
ES2294979T1 (en) * 2005-01-27 2008-04-16 Alembic Limited FORMULATION OF LONG-TERM LEVETIRACETAM.
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
AU2007254826B2 (en) * 2006-06-01 2013-10-24 Merck Sharp & Dohme Corp. Pharmaceutical compositions for sustained release of phenyephrine
CN101015519B (en) * 2007-02-27 2012-03-21 重庆医药工业研究院有限责任公司 Loratadine oral compound medication composition
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
CA2724533C (en) * 2008-07-24 2014-07-29 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
EP3045043B1 (en) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
CN102160859B (en) * 2011-02-23 2012-11-07 海南斯达制药有限公司 Loratadine and pseudoephedrine compound slow-release medicament
JP5752578B2 (en) * 2011-12-09 2015-07-22 ジェイ−メド ファーマシューティカルズ，インコーポレーティッド Single dose antihistamine / decongestant formulation for the treatment of rhinitis
CN104983708A (en) * 2015-06-24 2015-10-21 万特制药(海南)有限公司 Desloratadine sulfuric acid pseudoephedrine sustained release tablet and preparing method thereof
CN108576895B (en) * 2018-03-06 2021-04-30 特素生物科技（天津）有限公司 Slow-release nutritional staple food and preparation method thereof
WO2022023463A1 (en) 2020-07-30 2022-02-03 Faes Farma, S.A. Decongestant drug delivery system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
IE60311B1 (en) * 1987-09-24 1994-06-29 American Home Prod Sustained release etodolac
CN1053570C (en) * 1987-10-07 2000-06-21 默尔多药物公司 Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171618B1 (en) 1996-05-29 2001-01-09 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US6537573B2 (en) 1996-05-29 2003-03-25 Pfizer Inc Combination dosage form comprising cetirizine and pseudoephedrine

Also Published As

Publication number Publication date
HU9501143D0 (en) 1995-06-28
PL172862B1 (en) 1997-12-31
NZ257447A (en) 1996-09-25
US5314697A (en) 1994-05-24
AU676229B2 (en) 1997-03-06
WO1994009761A1 (en) 1994-05-11
FI112916B (en) 2004-02-13
NO308771B1 (en) 2000-10-30
DE69316023D1 (en) 1998-02-05
ES2110633T3 (en) 1998-02-16
HUT71682A (en) 1996-01-29
HU220629B1 (en) 2002-03-28
SK52295A3 (en) 1997-05-07
PH29940A (en) 1996-09-16
FI951901A (en) 1995-04-21
JP3580815B2 (en) 2004-10-27
CN1089471A (en) 1994-07-20
MY109090A (en) 1996-11-30
ATE161420T1 (en) 1998-01-15
TW251239B (en) 1995-07-11
CN1038474C (en) 1998-05-27
GR3026198T3 (en) 1998-05-29
KR100283709B1 (en) 2001-03-02
KR950703937A (en) 1995-11-17
NO951527D0 (en) 1995-04-21
CZ287687B6 (en) 2001-01-17
FI951901A0 (en) 1995-04-21
EE03106B1 (en) 1998-08-17
DE69316023T2 (en) 1998-04-23
JPH08502516A (en) 1996-03-19
CZ101495A3 (en) 1996-02-14
SK281090B6 (en) 2000-11-07
SG42947A1 (en) 1997-10-17
IL107354A0 (en) 1994-01-25
DK0665744T3 (en) 1998-09-07
EP0665744A1 (en) 1995-08-09
EP0665744B1 (en) 1997-12-29
AU5405094A (en) 1994-05-24
HK1004327A1 (en) 1998-11-20
ZA937830B (en) 1994-04-21
CA2147606C (en) 2000-10-10
NO951527L (en) 1995-06-20
IL107354A (en) 1998-02-08
PL308491A1 (en) 1995-08-07

Similar Documents

Publication Publication Date Title
CA2147606A1 (en) Stable Extended Release Oral Dosage Composition
CA2166483A1 (en) New Pharmaceutical Formulation
CA2329217A1 (en) Stable extended release oral dosage composition comprising desloratadine and pseudoephedrine
ATE145551T1 (en) Effervescent DOSAGE FORM AND METHOD FOR ADMINISTRATION THEREOF
NZ305166A (en) 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
NZ231247A (en) Two-layer pharmaceutical tablet containing analgesic and decongestant
CA2186039A1 (en) New oral pharmaceutical dosage form
EP0642788A3 (en)
GEP20033014B (en) Enteric Coated Pharmaceutical Composition and Method of Manufacturing
NO308854B1 (en) Therapeutic Compounds, Pharmaceutically Acceptable Salts and Formulations Containing the Compounds, and Uses thereof
HUT62192A (en) Process for producing pharmaceutical compositions comprising tomoxetine and suitable for treating diseases of lower urinary tract
AU5655696A (en) Pharmaceutical composition containing acetylcysteine, carboc ysteine or erdosteine in combination with a beta 2 agonist a nd an expectorant for the treatment of respiratory tract dis orders
NO20015806L (en) Pharmaceutical preparation containing a tetrahydrobenz [c, d] indole-6-carboxamide and use thereof
AU2700488A (en) Pharmaceutical compositions containing dyclonine hcl and phenol
AU1219092A (en) Substituted 2', 3'-dideoxy-5-trifluoromethyluridines, processes for their preparation and their use in medicaments
DE69026295T2 (en) Pharmaceutical composition against vasoconstriction diseases
AU8195091A (en) Ropinirole and domperidone for use in the manufacture of a medicament for the treatment of parkinson's disease
JO1821B1 (en) New phamaceutical formulation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20131021